What is the purpose of this study?Estimate complete remission (CR) rate per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate overall response rate (ORR) per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate duration of response (DOR) with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate progression free survival (PFS) with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate overall survival (OS) with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This study is a phase 3, double-blind, placebo-controlled, multicenter study of ASP3082 for the first-line treatment of participants with metastatic PDAC with KRAS G12D mutation in combination with mFOLFIRINOX or NALIRIFOX. The study will be conducted in approximately 250 study sites across Europe, Asia Pacific and the Americas (to ensure balance between countries, regional caps on enrollment may be implemented at the sponsor’s discretion). Potential participants will be screened for KRAS G12D mutation status based on local or central tests results and for prior chemotherapy treatment status. The screening period will last 45 days from ICF signing. Rescreening outside of the 45 day window under a new participant number may be allowed one time per participant, as needed, following discussion with the medical monitor. If rescreening occurs, KRAS G12D mutation status does not need to be retested. Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact:The IU Clinical Trials OfficeEmail: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this Phase 2 study is to assess the antimyeloma activity and further characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cemsidomide in combination with dexamethasone in subjects with relapsed/refractory multiple myeloma (r/r MM).Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

There are long-standing inequities in interventions for obesity among Black Breast Cancer Survivors (BCS).  While the American Cancer Society provides recommendations regarding weight management for successful cancer survivorship, the guidelines are not specific to women or Blacks.  This 3-phase pilot study will address these inequities by inviting Black BCS with obesity to contribute their voice in the development of a weight-related intervention for successful breast cancer survivorship and then test preliminary feasibility/acceptability and efficacy. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632